FIELD: chemistry.
SUBSTANCE: invention relates to use of peptides containing amino acid sequence KFARLWTEIPTAIT (SEQ ID NO: 1), FTEIPTI (SEQ ID NO: 3), for inhibiting angiogenesis and treating disorders associated with VEGF-induced vascular permeability, where the patient suffers from visual impairment or vision loss (blindness), macular degeneration, retinal central retinal occlusion, retinal vein occlusion, proliferative diabetic retinopathy, neovascular macular degeneration (NMD), premature retinopathy, ischemic retinopathy, intraocular neovascularisation, corneal neovascularisation, retinal neovascularisation, choroid neovascularisation, diabetic macular oedema, diabetic retinal ischemia, diabetic retinal oedema and proliferative diabetic retinopathy, iris palpebral iris, neovascular glaucoma, retinoblastoma, uveitis and corneal graft neovascularization.
EFFECT: disclosed are peptides for inhibiting angiogenesis.
20 cl, 12 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ATROPHIC AGE-RELATED MACULAR DEGENERATION | 2009 |
|
RU2521338C9 |
| OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF EYE DISEASES | 2018 |
|
RU2782355C2 |
| METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION | 2009 |
|
RU2668371C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING NRARP GENE EXPRESSION | 2016 |
|
RU2738971C2 |
| DEMETHYLATION FOR TREATMENT OF EYE DISEASE | 2019 |
|
RU2804300C2 |
